Fairvalue-Calculator Fairvalue-Calculator
EN DE

Medacta Group (MOVE) Fair Value & Analysis

Healthcare · CH · Market cap CHF 2.9B

PriceCHF 133.00
Fair ValueCHF 93.96
Upside-29.4%
Quality95/100
Evidence: High Range CHF 40.95 – CHF 148.40

Fair value as of: Jun 24, 2026

Analysis

Medacta Group (MOVE) currently trades at CHF 133.00, while our model-based Fair Value estimate is CHF 93.96 — implying the stock looks roughly 29.4% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Medacta Group SA develops, manufactures, and distributes orthopedic and neurosurgical medical devices Latin America, North America, the Asia-Pacific, and Middle East and Africa. It offers personalized 3D planning tools for use in hip, knee, shoulder, joint replacement, sports medicine, and spine surgery. The company was founded in 1958 and is headquartered in Castel San Pietro, Switzerland.

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -20% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

Frequently asked questions

Is Medacta Group (MOVE) undervalued?
As of Jun 24, 2026, our model estimates a fair value of CHF 93.96 versus a price of CHF 133.00 — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of MOVE?
Our 21-model fair value for Medacta Group is CHF 93.96 (as of Jun 24, 2026), built from audited fundamentals. The current price is CHF 133.00.
What is the quality score of MOVE?
Medacta Group has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.